RESUMO
PURPOSE: Superoxide dismutase (orgotein for injection) has been used in managing osteoarthritis for more than seven years in Europe; however, well-controlled studies to establish an optimum dosage regimen have not been conducted. In this study, three orgotein dose/regimens were compared with placebo in terms of efficacy, safety, and duration of effect in patients with active osteoarthritis of the knee. PATIENTS AND METHODS: A total of 139 patients with osteoarthritis of the knee were enrolled in the study. Nonsteroidal anti-inflammatory agents were withdrawn to induce a flare of disease activity. Patients were then randomly assigned to receive one intra-articular injection of either placebo or orgotein (8 mg to 32 mg) each week for three weeks. Both investigators and patients evaluated disease activity and adverse experiences at a series of follow-up visits for three months. RESULTS: Orgotein was effective in reducing symptoms of osteoarthritis for up to three months after treatment; 16 mg given twice was the most effective and most best-tolerated regimen. Discomfort at the injection site was drug related, although this effect also occurred occasionally after injection of placebo. CONCLUSION: The long-lasting effects of intra-articular superoxide dismutase contribute to a favorable risk-benefit ratio and support the importance of the free-radical anion, superoxide (O2-), in the biochemical pathology of osteoarthritis.
Assuntos
Articulação do Joelho , Metaloproteínas/administração & dosagem , Osteoartrite/tratamento farmacológico , Superóxido Dismutase/administração & dosagem , Idoso , Método Duplo-Cego , Esquema de Medicação , Feminino , Seguimentos , Humanos , Injeções Intra-Articulares , Masculino , Distribuição AleatóriaAssuntos
Anti-Inflamatórios/uso terapêutico , Artrite Reumatoide/tratamento farmacológico , Propionatos/administração & dosagem , Adulto , Anti-Inflamatórios/efeitos adversos , Ensaios Clínicos como Assunto , Feminino , Meia-Vida , Humanos , Masculino , Éteres Metílicos/administração & dosagem , Éteres Metílicos/efeitos adversos , Éteres Metílicos/uso terapêutico , Pessoa de Meia-Idade , Naftalenos/administração & dosagem , Naftalenos/efeitos adversos , Naftalenos/uso terapêutico , Placebos , Propionatos/efeitos adversos , Propionatos/uso terapêuticoRESUMO
The well informed and well motivated patient with rheumatoid arthritis today has an excellent chance of avoiding serious disability and deformity. No available pharmacologic agent can permanently alter the course of the disease, and no pharmacologic agent can preclude the need for a balanced program emphasizing moderation, rest and constant attention to physical therapy. Early synovectomy is enjoying increasing popularity although the long-term benefits have yet to be established. The several drugs now undergoing trial hold little promise of materially altering the management of rheumatoid arthritis in the near future. The skills of physician, surgeon, and physiatrist must be brought to bear to provide optimal care.
Assuntos
Artrite Reumatoide/terapia , Artrite Reumatoide/cirurgia , Tratamento Farmacológico , Humanos , Modalidades de FisioterapiaRESUMO
Subchondral cyst formation (geode) is a not uncommon manifestation of rheumatoid arthritis which may at times impede correct radiologic interpretation. Four patients with rheumatoid arthritis who demonstrated striking subarticular cystic erosive disease are described. These cases emphasize the nature and appearance of this interesting finding.
Assuntos
Artrite Reumatoide/diagnóstico por imagem , Adulto , Artrite Reumatoide/complicações , Cistos/etiologia , Feminino , Doenças do Pé/diagnóstico por imagem , Dermatoses da Mão/diagnóstico por imagem , Humanos , Articulação do Joelho/diagnóstico por imagem , Masculino , Pessoa de Meia-Idade , RadiografiaRESUMO
After baseline aspirin therapy, 89 rheumatoid arthritis patients completed a double-blind, crossover trial comparing ibuprofen, fenoprofen, naproxen, and tolmetin. Initially, patients took the manufacturer's recommended starting dose; this could be increased by 50% within the first 2 weeks of therapy. Patients remained at the chosen dose for 4 weeks and then changed to the next drug. All 4 drugs were tolerated better than aspirin (p less than 0.001). There were no statistically significant differences among the 4 drugs for any efficacy measurements. However, patients' and physicians' rankings showed the same order of preferences: naproxen, ibuprofen, fenoprofen, tolmetin, and aspirin.